HPV Vaccine Provides Decades of Cancer Protection in Landmark Study

Revolutionary Real-World Evidence

When researchers began tracking nearly 1.7 million Swedish women in 2006, they had no idea they would witness one of modern medicine's greatest success stories unfold. In what many global health leaders are calling a milestone study, researchers in Sweden have confirmed that widespread use of the human papillomavirus (HPV) vaccine dramatically reduces the number of women who will develop cervical cancer. In the study of nearly 1.7 million women, the vaccine's efficacy was particularly pronounced among girls vaccinated before age 17, among whom there was a nearly 90% reduction in cervical cancer incidence during the 11-year study period (2006 through 2017) compared with the incidence in women who had not been vaccinated.

Cervical cancer was diagnosed in 19 women who had received the quadrivalent HPV vaccine and in 538 women who had not received the vaccine. This stark difference demonstrates the vaccine's remarkable power to prevent what was once considered an inevitable consequence of HPV infection. HPV causes almost all cervical cancers and can also lead to other cancers in both men and women, including cancers of the throat, anus, penis, vagina, and vulva. Because these cancers usually develop slowly, often many years after infection, preventing the virus early is the most effective way to stop them.

Timing Makes All the Difference

We also found that the age at vaccination matters. Girls who received the vaccine before the age of 17 were much less likely to develop cervical cancer later in life. The Swedish study revealed that The Swedish researchers found an 87% reduction in invasive cervical cancer and a 97% reduction in high-grade precancerous lesions among young women who had the vaccine at ages 12 or 13. The impact was smaller with older girls: those vaccinated between ages 14 and 16 saw a 75% reduction in cervical cancer rates, while those vaccinated between 16 and 18 experienced a 39% reduction.

The vaccine prevents HPV infection, but it cannot remove an infection that has already occurred. Vaccinating earlier, ideally before exposure to the virus, allows the immune system to build protection in advance. This biological reality explains why vaccination programs target adolescents before they become sexually active, when the vaccine can provide maximum protection.

Protection That Lasts a Lifetime

One of the most encouraging discoveries from the research is the vaccine's durability. A common question about vaccines is whether their protection fades over time. The results of our study are reassuring. We followed participants for up to 18 years after vaccination and found no evidence that protection declined over time. Once the vaccine created protection, it continued working year after year.

Additional evidence from multiple countries reinforces this finding. A population-based study of all women born in Scotland between 1 January 1988 and 5 June 1996, linking immunisation, cervical screening and cancer registry data, found no cases of invasive cervical cancer among those vaccinated with the bivalent HPV vaccine (Cervarix) at ages 12-13 after 8-12 years of follow-up. Similarly, A national linkage study combining vaccination, pathology, and cancer registry data for 103,059 Dutch women, found that those fully vaccinated with the bivalent HPV vaccine (Cervarix) at age 16 had a 92% lower risk of cervical cancer and 81% lower risk of severe precancer after up to 15 years of follow-up, confirming strong protection lasting to at least age 30.

A Future Without HPV-Related Cancers

Cervical cancer is the fourth most common cancer in women worldwide and causes more than 300,000 deaths each year, mostly in low- and middle-income countries. The new reviews confirm that vaccination against HPV can prevent most of these cancers from developing. The implications extend far beyond individual protection, as HPV vaccines work remarkably well in a real-world setting, even among women at high risk for HPV and who may not have received all vaccine doses. Second, we saw clear evidence of herd immunity, meaning when enough people are vaccinated, the vaccine indirectly protects unvaccinated people by reducing overall virus transmission.

The transformation has been remarkable. Today, these powerfully effective vaccines have slashed HPV infection rates by 64 percent in the United States. As vaccination rates go up, there is already evidence of the potential to nearly eliminate HPV-caused cervical cancer in women coming of age and to prevent many other HPV-related cancers in both men and women. What began as a public health intervention has evolved into a cancer elimination strategy that could reshape the medical landscape for generations to come.